News from heptares therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 06, 2016, 02:42 ET Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has been...


Jun 29, 2016, 04:00 ET Heptares and Leadxpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and leadXpro AG...


Apr 28, 2016, 05:05 ET Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that Dr Fiona...


Apr 25, 2016, 11:05 ET Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease

  First structure of GLP-1 receptor in active state resolved   Novel allosteric binding site in glucagon receptor identified -...


Apr 18, 2016, 03:00 ET Heptares and Kymab Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and Kymab Limited, a leading...


Apr 06, 2016, 19:30 ET Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group...


Apr 04, 2016, 07:39 ET Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has partnered...


Feb 10, 2016, 01:30 ET Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity   Heptares Therapeutics ("Heptares"), the...


Feb 02, 2016, 04:00 ET Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS)

First collaboration initiated with Imperial College London  Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group...


Nov 30, 2015, 05:00 ET Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

Heptares Therapeutics ("Heptares"), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of...


Sep 28, 2015, 03:00 ET Heptares Awarded $5.5 Million Research & Development Grant From the US National Institute on Drug Abuse (NIDA)

Project to develop first-in-class Orexin-1 receptor antagonist for the treatment of cocaine addiction and dependence. Heptares Therapeutics...


Jun 17, 2015, 02:30 ET Heptares Announces Positive Outcome of Phase 1A Study with First-ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease

Early evidence of enhanced brain activity seen at dose levels that are well tolerated  Heptares Therapeutics, the clinical-stage GPCR...


Apr 16, 2014, 04:00 ET Heptares at Upcoming Diabetes and Neuroscience Partnering and Investment Conferences

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be...


Mar 26, 2014, 05:00 ET Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by...


Mar 07, 2014, 06:15 ET Heptares to Present at Upcoming Biotech Business Development Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that its Chief Executive Officer, Malcolm...


Jan 23, 2014, 04:00 ET Heptares Successfully Completes Research Phase of Antibody Discovery Collaboration with MedImmune

Stabilised GPCR (StaR®) Proteins Delivered For All Nominated Targets Heptares Therapeutics, the leading GPCR structure-guided drug discovery...


Jan 09, 2014, 04:00 ET Heptares Appoints Tim Tasker as Chief Medical Officer

Increases Focus on Clinical Development of Novel GPCR-targeted Drug Candidates Heptares Therapeutics, the leading GPCR structure-guided drug...


Jan 08, 2014, 04:00 ET Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel...


Dec 16, 2013, 04:00 ET Heptares Highlights Potential of StaR® Proteins as Antigens for GPCR-Targeted Antibody Discovery in New Scientific Publication

Biased Agonist Antibodies Generated To G Protein-Coupled Receptor Heptares Therapeutics, the leading GPCR structure-guided drug discovery and...


Dec 09, 2013, 03:00 ET Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease

First Human Trial of Novel Small Molecule Drug Derived From Heptares GPCR-Focused Structure-Based Drug Design Platform Heptares Therapeutics, the...